METHODS AND SYSTEMS FOR FUNCTIONAL MATURATION OF iPSC AND ESC DERIVED CARDIOMYOCYTES
US-2024076619-A1 · Mar 7, 2024 · US
Human cardiovascular progenitor cells
US10077428B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10077428-B2 |
| Application number | US-41078209-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 25, 2009 |
| Priority date | Mar 27, 2008 |
| Publication date | Sep 18, 2018 |
| Grant date | Sep 18, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides populations of human cardiovascular progenitor cells, methods of making such cells, and methods of using the cells for production of populations of cardiovascular colonies and populations of cardiomyocytes. Methods of cardiomyocytes replacement therapy are also provided.
First claim
Opening claim text (preview).
The invention claimed is: 1. An isolated population of human cardiovascular progenitor cells derived from human pluripotent stem cells in vitro, wherein the progenitor cells express KDR and do not express C-KIT and VE-CADHERIN and wherein the progenitor cells are progenitors of cardiomyocytes, endothelial cells, and vascular smooth muscle cells. 2. The population of human cardiovascular progenitor cells of claim 1 obtained by culturing human embryoid bodies in serum free media in the presence of activin and BMP. 3. The population of claim 2 wherein activin is activin A. 4. The population of claim 2 wherein BMP is BMP4. 5. A composition comprising the isolated population of human cardiovascular progenitor cells of claim 1 .
Assignees
Inventors
Classifications
Drugs for disorders of the cardiovascular system · CPC title
Activin; Inhibin; Mullerian inhibiting substance · CPC title
from embryonic cells · CPC title
Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00) · CPC title
Basic fibroblast growth factor (bFGF, FGF-2) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10077428B2 cover?
- The present invention provides populations of human cardiovascular progenitor cells, methods of making such cells, and methods of using the cells for production of populations of cardiovascular colonies and populations of cardiomyocytes. Methods of cardiomyocytes replacement therapy are also provided.
- Who is the assignee on this patent?
- Keller Gordon, Yang Lei, Kattman Steven, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0657. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).